SecBot SecBot
Biotech Drug Report Generated Aug 19, 2026

GAMUNEX-C

GRFS·Grifols, S.A.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (marketed); new Phase 3 label-expansion trial (SIGMA) just begun enrolling
Time to market
Already on the market (approved and commercialized). Label expansion into secondary immunodeficiency is estimated years away, readouts likely 2-3 years out per company commentary.
Why 4/10
Gamunex-C is already FDA-approved and marketed, and the only pending hard catalyst tied to it, the Phase 3 SIGMA topline readout for a secondary-immunodeficiency label expansion, is years away (first patients were dosed only in July 2026, with readouts estimated 2-3 years out), so there is no dated binary for this drug in the next ~12 months; per the rubric an approved drug with no pending regulatory decision caps at 3-5, and 4 reflects it being Grifols' flagship franchise.
Actionable Insight NEUTRAL

For Grifols (GRFS), Gamunex-C is a core revenue asset but not a near-term stock catalyst, the share-price drivers in the next ~12 months are company-wide (SPARTA Prolastin-C topline expected by end-2026, quarterly results), not Gamunex-C-specific. Watch SIGMA/XPERT enrollment updates for optionality, but treat the label-expansion payoff as a 2028+ event. Note the tape is mixed: positive analyst consensus and Q2 2026 13F accumulation by several managers, but also high short-volume flow and multiple 13F trims/exits.

Price Chart

Loading chart...

Executive Summary

GAMUNEX-C (immune globulin intravenous, human, IGIV-C) is Grifols' flagship FDA-approved intravenous immunoglobulin, already a commercial product; the defining approval binary long since passed. The relevant news is that in July 2026 Grifols dosed the first patients in two Phase 3 trials (SIGMA for GAMUNEX-C in secondary immunodeficiency, XPERT for its SCIg sibling XEMBIFY) to expand U.S. labels, a large (>1M U.S. patients) but years-away opportunity. Grifols' analyst consensus is mostly positive (9 Buy + 5 Strong Buy vs 2 Sell) and the mean price target of ~$10.87 implies ~40% upside from ~$7.75, though the target sample is just 2 analysts; Q2 2026 13F data is mixed (accumulation from BofA/Norges/Citadel, trims from JPMorgan/UBS/FMR/BMO).

How It Works

Gamunex-C is a concentrated solution of antibodies (immunoglobulins) purified from human blood plasma, given by IV infusion. It bolsters or replaces a patient's own immune defenses, used to treat people whose immune systems don't make enough antibodies (primary and secondary immunodeficiency) and certain autoimmune/nerve conditions where antibodies dampen the immune attack (e.g., CIDP, ITP). The July 2026 Phase 3 program aims to add a label indication for cancer patients whose immune systems are weakened by their disease or treatment.

Trial Status

Gamunex-C is an approved IVIg used in immune deficiency and neuro conditions (it is the active comparator in Grifols' XPERT CIDP non-inferiority trial). In July 2026 Grifols dosed the first patients in the Phase 3 SIGMA trial seeking a U.S. label expansion into secondary immunodeficiency in blood cancers (CLL, MM, NHL, a population of >1 million U.S. patients); it is an open-label, multicenter study with a reported ~50-patient sample. No efficacy data released; readout years out.

The Two-Sided Case

▲ Bull Case5
Already-approved, marketed flagship product generating revenue today; Grifols calls GAMUNEX-C and XEMBIFY its 'flagship immunoglobulins' and cites XEMBIFY growing nearly 60% YoY in 2025 as evidence of strong Ig-franchise demand (July 16, 2026 press release).
New Phase 3 SIGMA trial targets secondary immunodeficiency in hematologic cancers, a population of >1 million U.S. patients with CLL, MM and NHL, a meaningful label-expansion opportunity if it succeeds (press release report key facts).
Analyst setup positive: consensus 9 Buy + 5 Strong Buy vs 2 Sell/5 Hold, and mean price target $10.865 vs $7.75 last price (~40.2% implied upside), though based on only 2 analysts' targets.
Q2 2026 13F showed accumulation by several tracked managers: BofA +51.4%, Norges Bank new position, Citadel +437%, BlackRock +34.3%.
Short interest is low and falling: 3,455,645 shares short as of the 2026-07-31 settlement, -45.5% vs prior period, ~0.50% of estimated shares outstanding.
▼ Bear Case4
No near-term binary for THIS drug: SIGMA/XPERT are just starting enrollment (first dose July 2026) with readouts estimated 2-3 years out, so label-expansion revenue is far away (press release report actionableInsight).
Phase 3 and regulatory risk: trial failure or enrollment delays could derail label expansion, and Ig products carry safety risks such as thrombotic events (press release report risk list).
Competition: CSL Behring, Takeda and others market competing immunoglobulin therapies that could limit share gains even if labels expand (press release report risk list).
Company-level tape is mixed-to-bearish: SecBot's 90-day bull/bear evidence checklist nets bearish, high FINRA short-volume flow (weighted short-volume ratio ~0.36 over 58 sessions) plus numerous 13F trims/exits including BMO -90.9% near-exit, FMR -64.9%, JPMorgan -28.6%, UBS -42.1%, GEODE -37.1%.

Upcoming Catalysts

  • SPARTA Phase 3 (Prolastin-C, a different Grifols drug): clinical portion completed Aug 2026; topline results expected by end of 2026, the nearest dated company catalyst, but not Gamunex-C.
  • SIGMA (Gamunex-C SID) and XPERT (XEMBIFY CIDP) Phase 3 enrollment updates, no dated readout yet; likely 2-3 years out.
  • Grifols quarterly results and SEC 6-K/20-F filings (20-F filed 2026-04-17; periodic 6-Ks).
  • Analyst actions / price-target updates (consensus refreshed Aug 2026) and 13F disclosures for Q3 2026.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Grifols, S.A. Press Release GRFS ·Originating report

Sources · 6

Hover a chip for the title
1 globenewswire.com2 globenewswire.com3 globenewswire.com4 sec.gov5 sec.gov6 sec.gov